Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01147692 · ClinicalTrials.gov registry record · Phase 1
A Drug Interaction Study of Simvastatin and Albiglutide
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01147692 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 40 participants.
The verdict
NCT01147692, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This open-label study evaluates the pharmacokinetics of simvastatin when coadministered with albiglutide in healthy adult subjects. The primary objective is to assess the effect of albiglutide doses on the pharmacokinetics of simvastatin.
Interventions
- BIOLOGICAL simvastatin plus albiglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2010-05-19 |
| Est. Completion | 2010-08-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01147692
The ClinicalTrials.gov registry entry for NCT01147692 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which simvastatin plus albiglutide is the first listed.
NCT01147692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01147692 about?
NCT01147692 is a clinical study titled "A Drug Interaction Study of Simvastatin and Albiglutide". This open-label study evaluates the pharmacokinetics of simvastatin when coadministered with albiglutide in healthy adult subjects. The primary objective is to assess the effect of albiglutide doses on the pharmacokinetics of simvastatin.
What is the current status of trial NCT01147692?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2010-05-19. Estimated completion is 2010-08-27.
What interventions are being tested in trial NCT01147692?
The interventions under investigation include: simvastatin plus albiglutide (BIOLOGICAL).
Who is sponsoring clinical trial NCT01147692?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.